Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed  by Xie, Zhidong et al.
Serotonin 5-HT1B and 5-HT1D receptors form homodimers when
expressed alone and heterodimers when co-expressed
Zhidong Xiea, Samuel P. Leea;c, Brian F. O’Dowda;c, Susan R. Georgea;b;c;*
a Department of Pharmacology, University of Toronto, Room 4358, Medical Sciences Building, 1 King’s College Circle,
Toronto, Ont. M5S 1A8, Canada
b Department of Medicine, University of Toronto, Toronto, Ont. M5S 1A8, Canada
c The Centre for Addiction and Mental Health, Toronto, Ont. M5S 2S1, Canada
Received 23 April 1999
Abstract The serotonin (5-hydroxytryptamine (5-HT)) 1B and
1D receptor subtypes share a high amino acid sequence identity
and have similar ligand binding properties. In this study, we
demonstrate that both receptor subtypes exist as monomers and
homodimers when expressed alone and as monomers and
heterodimers when co-expressed. Gene expression studies have
shown that there are brain regions where the 5-HT1B and 5-HT1D
receptors are co-localized and where heterodimerization may
occur physiologically. This is the first direct visualization of the
physical association between G protein-coupled receptors of
different subtypes.
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1. Introduction
The serotonin (5-hydroxytryptamine (5-HT)) receptors are
a large and complex family of receptors [1]. Many more re-
ceptor subtypes have been discovered through molecular clon-
ing than was predicted by pharmacological studies [2]. All 5-
HT receptors, except those in the 5-HT3 subfamily, are G
protein-coupled receptors (GPCRs) and 5-HT-mediated signal
transduction occurs through a variety of e¡ectors. The diver-
sity in the structure and function of 5-HT receptors has not
only complicated the classi¢cation of these receptors, it has
also created di⁄culties in understanding their physiological
roles [2].
The 5-HT1 receptors represent the largest subclass of 5-HT
receptors and are de¢ned in part by their preferential coupling
to the Gi=o class of G proteins [3]. Our group was the ¢rst to
report the cloning of the human gene encoding one of these
5-HT1 subtypes, the 5-HT1B receptor [4]. Extensive studies of
the 5-HT1B receptor have been carried out. However, charac-
terization of this receptor in vivo has been hindered due to the
existence of the closely related 5-HT1D receptor. The 5-HT1B
and 5-HT1D receptors share V68% amino acid sequence ho-
mology and are almost indistinguishable pharmacologically
[5,6]. This similarity in the ligand binding properties has cre-
ated problems in distinguishing the receptor subtypes in vivo
and in establishing their respective physiological relevance [7].
Following the cloning of the 5-HT1B receptor gene, we also
examined signal transduction mechanisms and post-transla-
tional modi¢cations of the 5-HT1B receptor [8]. During these
studies, it was observed that the 5-HT1B receptor exists as
monomers and homodimers. There is increasing evidence
that all GPCRs form oligomeric structures. We have shown
that heterologously expressed D1 and D2 dopamine receptors
exist as homodimers [9,10] and, recently, we have demon-
strated that D2 dopamine receptors exist as dimers in human
and rat brain tissue [11]. Observations have been made sug-
gesting that the M2 muscarinic [12], the L2-adrenergic [13], the
V2 vasopressin [13], the metabotropic glutamate [14], the H2
histamine [15], the N-opioid [16], the D3 dopamine [17] and
the Ca2-sensing [18] receptors also form dimers, demonstrat-
ing that oligomerization may be a universal aspect of GPCR
biology.
In this study, we examined the dimeric states of the 5-HT1B
and 5-HT1D receptors. We predicted that, like the 5-HT1B
receptor, the 5-HT1D receptor would form dimers. In addi-
tion, we hypothesized that the 5-HT1B and 5-HT1D receptors
would form heterodimers when co-expressed. The basis for
our hypothesis was 2-fold. Firstly, while the precise site(s)
of interaction between two monomeric GPCRs undergoing
dimerization has not been elucidated, it has been postulated
that receptor-receptor interactions between the transmem-
brane (TM) domains may be involved [13,19]. The homology
between the 5-HT1B and 5-HT1D receptors in the TM domains
is 77%. Therefore, we postulated that receptor-receptor inter-
actions similar to those involved in homodimerization could
occur between these two closely related 5-HT receptor sub-
types. Secondly, there appears to be a large degree of overlap
in the anatomical localization of the two receptors [20]. We
were intrigued by the possibility that 5-HT1B and 5-HT1D
receptors may be co-localized in vivo and that they may
form heterodimers in these areas of co-expression.
In this investigation, in addition to demonstrating that both
the 5-HT1B and 5-HT1D receptors form homodimers when
expressed alone, we provide direct evidence of their heterodi-
merization, indicating a physical association of the 5-HT1B
receptor with the 5-HT1D receptor.
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2. Materials and methods
2.1. Construction of c-myc-tagged 5-HT1B and 5-HT1D receptor
baculoviruses
The 5-HT1B receptor cDNA and 5-HT1D receptor cDNA were
modi¢ed using the Transformer Site Directed Mutagenesis kit (Clon-
tech). A DNA sequence encoding an 11 residue c-myc epitope (EQ-
KLISEEDLN) was inserted after the codon encoding the N-terminal
start methionine. Recombinant baculovirus was created from the re-
sulting c-myc-tagged receptor cDNA using the Bac-to-Bac kit (Life
Technologies).
2.2. Cell culture
All culture media, antibiotics and supplements were purchased from
Life Technologies. Sf9 cells were maintained at 27‡C in Grace’s Insect
Media supplemented with 10% (v/v) fetal bovine serum, 0.5Uantibi-
otic-antimycotic and 1% (v/v) Pluronic F-68, a surfactant. Suspension
cultures were infected with baculovirus when the cell density was
1^3U106 cells/ml with a multiplicity of infection of approximately
5. Membranes were prepared from the cells 48 h after infection unless
otherwise noted.
2.3. Membrane preparation
Cells were washed with phosphate-bu¡ered saline, resuspended in
hypotonic lysis bu¡er (5 mM Tris-HCl, 2 mM EDTA, 5 Wg/ml leu-
peptin, 10 Wg/ml benzamide, 5 Wg/ml soybean trypsin inhibitor, pH
7.4) and homogenized by Polytron (Brinkman). The homogenate was
centrifuged to a pellet of unbroken cells and nuclei. The supernatant
was collected and centrifuged at 40 000Ug for 20 min and the result-
ing pellet was washed and resuspended in lysis bu¡er.
2.4. Radioligand binding assays
Saturation binding and competition binding assays were performed
as previously described [8]. Brie£y, for saturation experiments, 20^
25 Wg of membranes from receptor-expressing cells was incubated
with increasing concentrations of [3H]5-carboxamidotryptamine (5-
CT) (NEN Life Sciences Products) or [3H]GR-125743 (Amersham
Pharmacia Biotech). The reaction volume was 0.5 ml and the binding
bu¡er consisted of 50 mM Tris-HCl, 5 mM EDTA, 1.5 mM CaCl2,
5 mM MgCl2, 5 mM KCl and 120 mM NaCl with a pH of 7.4. Non-
speci¢c binding was de¢ned using 100 WM methysergide (RBI) or
mesulergine (RBI).
For competition binding experiments, 20^25 Wg of membranes was
incubated with V1 nM [3H]5-CT or V10 nM [3H]GR-125743 and
increasing concentrations of competing drugs.
For both assays, binding reactions were incubated at room temper-
ature for 2 h to reach equilibrium. Bound radioligand was then iso-
lated from free radioligand by rapid ¢ltration through a Brandel
48 well harvester using Whatman GF/C ¢lters. Data were analyzed
using non-linear least-squares regression equations on the curve-¢tting
computer program Prism v2.01 (Graphpad).
2.5. Gel electrophoresis and immunoblotting
The protein samples were subjected to sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) under reducing condi-
tions using 10 or 12% pre-cast acrylamide gels (Novex) and trans-
ferred to nitrocellulose using a semi-dry transfer apparatus. The
nitrocellulose was blocked using 10% (w/v) skim milk powder in
Tris-bu¡ered saline (TBS) and then incubated in 1% skim milk pow-
der TBS containing the 9E10 antibody (Santa Cruz Biotechnology).
The primary antibody was detected using horseradish peroxidase-con-
jugated goat anti-mouse IgG (Bio-Rad) and the Enhanced Chemilu-
minescent detection kit (Amersham). The relative intensities of bands
detected by immunostaining were determined using re£ective densi-
tometry and the Gel Doc 1000 Video Documentation System and
Molecular Analyst software (Bio-Rad).
3. Results
3.1. The 5-HT1B and 5-HT1D receptors formed homodimers
when expressed alone
Immunoblot analysis of cells expressing the 5-HT1B recep-
tor revealed bands with apparent molecular weights of V43
and V86 kDa, corresponding to 5-HT1B receptor monomers
and dimers (Fig. 1, lane 1). In cells expressing the 5-HT1D
receptor, bands with apparent molecular weights of V38
and V76 kDa representing 5-HT1D receptor monomers and
dimers were immunodetected (Fig. 1, lane 2). 5-HT1B and 5-
HT1D receptor monomers are predicted by sequence analysis
to be V43 and V38 kDa, respectively. The immunoreactive
bands representing receptor monomers are close to their pre-
dicted molecular weight because proteins expressed using the
baculovirus/Sf9 cell system are not subject to heavy glycosy-
lation [21].
Membranes from cells expressing 5-HT1B and 5-HT1D re-
ceptors were mixed, subjected to SDS-PAGE and immuno-
blotted. Proteins corresponding in molecular weight to 5-
HT1B and 5-HT1D receptor monomers and homodimers
were immunodetected (Fig. 1, lane 3).
3.2. The 5-HT1B and 5-HT1D receptors formed heterodimers
when co-expressed
Membranes from cells co-expressing the 5-HT1B and 5-
HT1D receptors were immunoblotted (Fig. 2, lane 2). Immu-
noreactive bands corresponding to 5-HT1B and 5-HT1D recep-
tor monomers were detected. However, no band correspond-
ing in molecular weight to either receptor homodimer was
observed (Fig. 2, lane 2). An V80 kDa protein was immuno-
detected which, being intermediate in size, corresponded to 5-
HT1B receptor/5-HT1D receptor heterodimer and which was
not observed in cells expressing only one of the receptor sub-
types (Fig. 2, lanes 1 and 3) or in the mixed membranes (Fig.
1, lane 3).
3.3. Ligand binding properties of cells co-expressing
the 5-HT1B and 5-HT1D receptors
Saturation and competition binding assays were performed
Fig. 1. Immunoblot analysis of membranes from Sf9 cells expressing
the 5-HT1B receptor (lane 1) and the 5-HT1D receptor (lane 2) and
of a mixture of both membranes (lane 3). Both receptors were
c-myc epitope-tagged and the 9E10 monoclonal antibody was used
for immunodetection. For each lane, 25 Wg of protein was used.
The immunoblot shown is representative of three independent ex-
periments.
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on membranes expressing the 5-HT1B receptor alone, express-
ing the 5-HT1D receptor alone and co-expressing both recep-
tor subtypes. A mixture of membranes expressing only one
subtype with membranes expressing only the other subtype
was also tested. The a⁄nity constants of the non-selective
agonist 5-CT and the 5-HT1 antagonist GR-125743 were cal-
culated to be 1.2 and 2.6 nM, respectively, for the 5-HT1B
receptor and 0.9 and 2.8 nM, respectively, for the 5-HT1D
receptor. Co-expression of the receptor subtypes did not alter
the a⁄nity for 5-CT or GR-125743 (1.1 nM for 5-CT and 2.9
nM for GR-125743).
Saturation binding with [3H]ketanserin, an antagonist with
a higher a⁄nity for the 5-HT1D receptor compared to 5-HT1B
receptor, was also performed. As expected, the a⁄nity of ke-
tanserin for the 5-HT1D receptor (2.8 nM) was slightly higher
than for the 5-HT1B receptor (9.2 nM). However, no signi¢-
cant change in ketanserin a⁄nity was seen in membranes co-
expressing both receptors (9.0 nM).
In competition binding assays, [3H]GR-125743 was dis-
placed by the non-selective antagonist methysergide (Fig. 3)
and [3H]5-CT was displaced by ketanserin (Fig. 4). The inhib-
itory binding constant (Ki) of methysergide was almost iden-
tical for the 5-HT1B receptor compared to the 5-HT1D recep-
tor. For the co-expressed 5-HT1B/5-HT1D receptors, the Ki
value was not di¡erent from that of the receptors expressed
alone.
Two a⁄nity states were detected for ketanserin competition
of [3H]5-CT for the 5-HT1B receptor, 5-HT1D receptor and the
co-expressed receptors (Fig. 4). The Ki values for the high and
low a⁄nity states were both approximately one log unit high-
er for the 5-HT1D receptor compared to 5-HT1B receptor. For
membranes co-expressing the receptors, analysis of a four
state model was not performed. However, when the binding
data were subjected to a two state analysis, the high and low
a⁄nity state inhibitory constants approximated an average of
constants for the two receptors expressed alone.
4. Discussion
We have shown that the serotonin 5-HT1B and 5-HT1D
receptors form homodimers when expressed alone and heter-
odimers when co-expressed. This represents a direct demon-
stration of the physical association between two GPCR sub-
types. No heterodimers were observed when membranes
expressing one receptor subtype were mixed with membranes
expressing only the other, indicating that heterodimerization
in cells may require a speci¢c cellular mechanism and does not
result from non-speci¢c aggregation of the receptors.
Interestingly, when the 5-HT1B and 5-HT1D receptors were
co-expressed, no homodimers were observed. This suggests
that, when co-expressed, the receptors favor the heterodimeric
conformation. It has been shown that there are regions of the
Fig. 2. Immunoblot analysis of membranes from Sf9 cells expressing
the 5-HT1B receptor alone (lane 1) and the 5-HT1D receptor alone
(lane 3) and membranes co-expressing both receptors (lane 2). Both
receptors were c-myc epitope-tagged and the 9E10 monoclonal anti-
body was used for immunodetection. For each lane, 25 Wg of pro-
tein was used. The immunoblot shown is representative of three in-
dependent experiments.
Fig. 3. Competition of [3H]GR-125743 binding with methysergide in
membranes prepared from Sf9 cells expressing the 5-HT1B receptor
(b) or the 5-HT1D receptor (F) or co-expressing both receptors (R).
The inhibitory binding constants (Ki) calculated from the binding
data are shown in the inset table.
Fig. 4. Competition of [3H]5-CT binding with ketanserin in mem-
branes prepared from Sf9 cells expressing the 5-HT1B receptor alone
(b) or the 5-HT1D receptor alone (F) or co-expressing both recep-
tors (R). The inhibitory binding constants (Ki) for the high and
low a⁄nity binding states calculated from the binding data are
shown in the inset table.
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brain where both of these 5-HT receptor subtypes occur to-
gether and there are regions in which expression of only one
subtype occurs. For example, the 5-HT1B and 5-HT1D recep-
tors are found to be both expressed in the cerebral cortex, the
olfactory tubercle and the dorsal raphe nucleus [20]. The
5-HT1B receptor is expressed without the 5-HT1D receptor in
the anterior caudate putamen, hypothalamus, thalamus and
hippocampus and the 5-HT1D receptor is expressed in the
trigeminal nucleus and parts of the cerebellum, regions where
the 5-HT1B receptor does not occur [20]. This raises the pos-
sibility that two receptor subtypes could result in three pop-
ulations of receptor complexes: two homodimeric and one
heterodimeric.
The concept of hetero-oligomeric arrangements between
closely related receptors may be novel within the GPCR fam-
ily, however, the formation of ‘hybrid’ receptors among hor-
mone receptors and growth factor receptors is commonly ac-
cepted as a mechanism for increasing the diversity of cellular
responses to extracellular signals. The existence of hybrid re-
ceptors between the insulin-like growth factor receptor and
the insulin receptor, between subtypes of the platelet-derived
growth factor receptors and between the T3 thyroid hormone
receptor and the retinoic acid receptor has been well-estab-
lished (reviewed in [22]).
Our ligand binding experiments revealed no signi¢cant dif-
ferences between ligand a⁄nity pro¢les in membranes express-
ing one of the 5-HT1B or 5-HT1D receptors alone and mem-
branes co-expressing both 5-HT receptor subtypes. This
¢nding di¡ers from our observations in the D2 dopamine
receptor. We have shown that dimers of the D2 dopamine
receptor have di¡erent binding characteristics than receptor
monomers [11,23], indicating that the association of two
GPCRs may result in an alteration of the existing ligand bind-
ing pockets or the creation of novel binding sites. Our obser-
vations with the 5-HT1B and 5-HT1D receptors suggest that a
novel or altered binding pocket did not result from heterodi-
merization. Since our binding experiments indicated no di¡er-
ences between co-expressed 5-HT1B and 5-HT1D receptors and
the receptors expressed alone, it is possible that heterodimers
of these closely related receptor subtypes do not possess novel
binding characteristics but may di¡er in another functional
aspect related to receptor structure.
Interestingly, suggestions of cross-talk among serotonin re-
ceptor subtypes and between serotonin receptors and other
receptors have recently been made [24^26]. While current
thinking on this matter speculates that this type of association
between di¡erent receptors occurs at the e¡ector level, our
data suggest the novel possibility that cross-talk may be at
the level of the receptor as well.
During the course of our work, hetero-oligomerization be-
tween the two known metabotropic Q-aminobutyric acid
(GABA) receptor subtypes GABABR1 and GABABR2 was
reported [27^30]. However, the conclusion that GABABR1
and GABABR2 form hetero-oligomers was made without di-
rect visualization of heterodimeric protein complexes. Fur-
thermore, while the GABAB receptors are GPCRs, they are
members of a distinct subfamily sometimes referred to as the
family C [31]. The 5-HT GPCRs are members of the rhodop-
sin-like GPCRs or family A [32].
In conclusion, this study represents the ¢rst direct visual-
ization of GPCR heterodimerization and the ¢rst demonstra-
tion that rhodopsin-like GPCRs form heterodimers. While the
precise role of homodimeric and heterodimeric 5-HT1B and 5-
HT1D receptors remains to be elucidated, it is possible that the
phenomenon may be exploited therapeutically. For instance,
it has been shown that dimeric serotonin ligands are more
potent than their monomeric equivalents at the 5-HT1B and
5-HT1D receptors [33,34]. It will be interesting to determine if
heterodimerization occurs among other serotonin receptor
subtypes and other GPCRs resulting in a greater diversity
of the GPCR function than that predicted by the number of
cloned receptor genes.
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